Insulinoma classification: Difference between revisions

Jump to navigation Jump to search
Line 36: Line 36:
  | pmid = 01677058
  | pmid = 01677058
}}</ref>
}}</ref>
*Insulinoma being a pancreatic neuroendocrine tumor may be classified into several subtypes based on Ameri:
**[classification method 1]
**[classification method 2]
**[classification method 3]
OR


* Previously insulinoma was classified into 2 subtypes based on hormonal level as determined by radioimmunoassay<ref name="pmid6311653">{{cite journal| author=Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H et al.| title=Functional and morphologic characterization of human insulinomas. | journal=Diabetes | year= 1983 | volume= 32 | issue= 10 | pages= 921-31 | pmid=6311653 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6311653  }} </ref>:  
* Previously insulinoma was classified into 2 subtypes based on hormonal level as determined by radioimmunoassay<ref name="pmid6311653">{{cite journal| author=Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H et al.| title=Functional and morphologic characterization of human insulinomas. | journal=Diabetes | year= 1983 | volume= 32 | issue= 10 | pages= 921-31 | pmid=6311653 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6311653  }} </ref>:  
Line 41: Line 46:
**Group B of scarce B cells with medullary arrangement and irregular immunofluorescence
**Group B of scarce B cells with medullary arrangement and irregular immunofluorescence
*  
*  
*[Disease name] may be classified into several subtypes based on:
 
**[classification method 1]
**[classification method 2]
**[classification method 3]
OR
*Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
*Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
OR

Revision as of 16:13, 10 August 2017

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma classification

CDC on Insulinoma classification

Insulinoma classification in the news

Blogs on Insulinoma classification

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

  • There is no established system for the classification of [disease name].

OR

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

  • [Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
  • [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

  • Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

  • If the staging system involves specific and characteristic findings and features:
  • According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

  • The staging of [malignancy name] is based on the [staging system].

OR

  • There is no established system for the staging of [malignancy name].

Classification

  • Insulinoma may be classified according to malignant potential into 2 subtypes/groups:
    • Benign
    • Malignant
      • 90% of insulinoma are benign in nature while 10% has a malignant potential to invade adjacent soft tissues or structures. The malignant type is mostly associated with MEN 1 syndrome.They also have a recurrence rate which is higher in those with MEN1 (21% at 10 and 20 years) than without it(5% at 10 and 7% at 20 years)[1]
  • Insulinoma being a pancreatic neuroendocrine tumor may be classified into several subtypes based on Ameri:
    • [classification method 1]
    • [classification method 2]
    • [classification method 3]

OR

  • Previously insulinoma was classified into 2 subtypes based on hormonal level as determined by radioimmunoassay[2]:
    • Group A of abundant B cells with trabecular arrangement and uniform insulin immunofluorescence
    • Group B of scarce B cells with medullary arrangement and irregular immunofluorescence
  • Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

  • If the staging system involves specific and characteristic findings and features:
  • According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

  • The staging of [malignancy name] is based on the [staging system].

OR

  • There is no established system for the staging of [malignancy name].

References

  1. F. J. Service, M. M. McMahon, P. C. O'Brien & D. J. Ballard (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clinic proceedings. 66 (7): 711–719. PMID 01677058. Unknown parameter |month= ignored (help)
  2. Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H; et al. (1983). "Functional and morphologic characterization of human insulinomas". Diabetes. 32 (10): 921–31. PMID 6311653.

Template:WH Template:WS